Chapter title |
Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology.
|
---|---|
Chapter number | 1 |
Book title |
Novel Natural Products: Therapeutic Effects in Pain, Arthritis and Gastro-intestinal Diseases
|
Published in |
Fortschritte der Arzneimittelforschung Progress in drug research Progrès des recherches pharmaceutiques, January 2015
|
DOI | 10.1007/978-3-0348-0927-6_1 |
Pubmed ID | |
Book ISBNs |
978-3-03-480926-9, 978-3-03-480927-6
|
Authors |
Vitetta, Luis, Palacios, Talia, Hall, Sean, Coulson, Samantha, Luis Vitetta, Talia Palacios, Sean Hall, Samantha Coulson |
Abstract |
Bacteria represent the earliest form of independent life on this planet. Bacterial development has included cooperative symbiosis with plants (e.g., Leguminosae family and nitrogen fixing bacteria in soil) and animals (e.g., the gut microbiome). It is generally agreed upon that the fusion of two prokaryotes evolutionarily gave rise to the eukaryotic cell in which mitochondria may be envisaged as a genetically functional mosaic, a relic from one of the prokaryotes. This is expressed by the appearance of mitochondria in eukaryotic cells (an alpha-proteobacteria input), a significant endosymbiotic evolutionary event. As such, the evolution of human life has been complexly connected to bacterial activities. Hence, microbial colonization of mammals has been a progressively driven process. The interactions between the human host and the microbiome inhabiting the gastrointestinal tract (GIT) for example, afford the human host the necessary cues for the development of regulated signals that in part are induced by reactive oxygen species (ROS). This regulated activity then promotes immunological tolerance and metabolic regulation and stability, which then helps establish control of local and extraintestinal end-organ (e.g., kidneys) physiology. Pharmacobiotics, the targeted administration of live probiotic cultures, is an advancing area of potential therapeutics, either directly or as adjuvants. Hence the continued scientific understanding of the human microbiome in health and disease may further lead to fine tuning the targeted delivery of probiotics for a therapeutic gain. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 1% |
Unknown | 76 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 16% |
Researcher | 10 | 13% |
Student > Master | 9 | 12% |
Other | 8 | 10% |
Student > Ph. D. Student | 5 | 6% |
Other | 12 | 16% |
Unknown | 21 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 29% |
Biochemistry, Genetics and Molecular Biology | 8 | 10% |
Agricultural and Biological Sciences | 8 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Psychology | 4 | 5% |
Other | 7 | 9% |
Unknown | 24 | 31% |